

ISSUE @ A GLANCE



A revolution in diabetes care: novel drugs and new recommendations
T.F. Lüscher

195

CardioPulse

Vera Regitz-Zagrosek MD PhD

A. Tofield

199

Animals in cardiovascular research

N. Cesarovic, M. Lipski, V. Falk, and M.Y. Emmert

200

The Fourth European-South African Cardiovascular Research Workshop

S. Lecour, D.J. Hausenloy, and R. Madonna

203

Cardiology care delivered to cancer patients

R. Asteggiano, V. Aboyans, G. Lee, S. Salinger, and D. Richter

205

IRIS courses for cardiology

L. Bacharova, D. Komarova, and A. Böhm

207

New EHJ International Editorial Board Member

208


FAST TRACK CLINICAL RESEARCH

Disease management

Relationship between hypoglycaemia, cardiovascular outcomes, and empagliflozin treatment in the EMPA-REG OUTCOME[®] trial

D. Fitchett, S.E. Inzucchi, C. Wanner, M. Mattheus, J.T. George, O. Vedin, B. Zinman, and O.E. Johansen; on behalf of the EMPA-REG Outcome[®] Trial Investigators

209



Patients at risk	0	6	12	18	24	30	36	42	48
Placebo	2333	1974	1847	1730	1479	1057	876	563	127
Empagliflozin	4687	3874	3621	3431	3008	2168	1811	1186	277

Editorial

A new perspective on lowering CV risk from hypoglycaemia

C. Solis-Herrera, O. Sheikh, and R. Chilton

218

CLINICAL RESEARCH

Vascular medicine

Body mass index and body composition in relation to 14 cardiovascular conditions in UK Biobank: a Mendelian randomization study

S.C. Larsson, M. Bäck, J.M.B. Rees, A.M. Mason, and S. Burgess

221

Editorial

Obesity causes cardiovascular diseases: adding to the weight of evidence


A.D. Hingorani, C. Finan, and A.F. Schmidt

227

Prevention and epidemiology

Resting heart rate and cardiovascular outcomes in diabetic and non-diabetic individuals at high cardiovascular risk analysis from the ONTARGET/TRANSCEND trials

M. Böhm, H. Schumacher, K.K. Teo, E.M. Lonn, F. Mahfoud, C. Ukena, J.F.E. Mann, G. Mancía, J. Redon, R.E. Schmieder, K. Sliwa, N. Marx, M.A. Weber, B. Williams, and S. Yusuf 231



BASIC SCIENCE

Lipids

Cyclase-associated protein 1 is a binding partner of proprotein convertase subtilisin/kexin type-9 and is required for the degradation of low-density lipoprotein receptors by proprotein convertase subtilisin/kexin type-9

H.-D. Jang, S.E. Lee, J. Yang, H.-C. Lee, D. Shin, H. Lee, J. Lee, S. Jin, S. Kim, S.J. Lee, J. You, H.-W. Park, K.-Y. Nam, S.-H. Lee, S.W. Park, J.-S. Kim, S.-Y. Kim, Y.-W. Kwon, S.H. Kwak, H.-M. Yang, and H.-S. Kim 239

Editorial

A tip of the CAP1 to cholesterol metabolism

J.S. Dron and R.A. Hegele 253

ESC GUIDELINES

2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD

F. Cosentino, P.J. Grant, V. Aboyans, C.J. Bailey, A. Ceriello, V. Delgado, M. Federici, G. Filippatos, D.E. Grobbee, T.B. Hansen, H.V. Huikuri, I. Johansson, P. Jüni, M. Lettino, N. Marx, L.G. Mellbin, C.J. Östgren, B. Rocca, M. Roffi, N. Sattar, P.M. Seferović, M. Sousa-Uva, P. Valensi, and D.C. Wheeler 255

DISCUSSION FORUM

The possible role of insulin and glucagon in patients with heart failure and Type 2 diabetes

M. Skelin, M. Lucijanic, and E. Javor 325

Response to 'The possible role of insulin and glucagon in patients with heart failure and Type 2 diabetes'

E. Bertero, V. Sequeira, S. Heymans, and C. Maack 326

Comments on the 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases

A. Jorsal, F. Persson, and J.M. Bruun 328

Compelling evidence for SGLT2 inhibitors and GLP-1 receptor agonists as first-line therapy in patients with diabetes at very high/high cardiovascular risk

N. Marx, P.J. Grant, and F. Cosentino 329

Treatment algorithm in patients with type 2 diabetes and atherosclerotic cardiovascular disease or high/very high cardiovascular risk

G. Targher and C.D. Byrne 331

CARDIOVASCULAR FLASHLIGHTS

Amphetamine-induced coronary artery dissection and massive aortic valve thrombus

M. Eberhard, M. Hermann, B.E. Stähli, R. Manka, F. Maisano, and H. Alkadhi

230

Complete regression of coronary atherosclerosis

H.S. Lee, M. Chang, M. Piccinelli, and B.-K. Koo

332

 Open Access Paper



For the podcast associated with this article, please visit <https://academic.oup.com/eurheartj/pages/Podcasts>



Visit EHJ's mobile site

<https://academic.oup.com/eurheartj>



www.eurheartj.org